The papillomavirus major capsid protein L1

Virology

Volumn 445, Issue 1-2, 2013, Pages 169-174

  Buck, Christopher B ^a   Day, Patricia M ^a   Trus, Benes L ^b  

^a NCI   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

HPV; HPV16; L2; Maturation; Papillomaviridae; Virion

Indexed keywords

CAPSID PROTEIN L1; GENOMIC DNA; RECOMBINANT PROTEIN; VIRUS DNA; WART VIRUS VACCINE;

ARTICLE; CONFORMATIONAL TRANSITION; HOST CELL; IMMUNOGENICITY; LIFE CYCLE; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN FUNCTION; VIRION; VIRUS ATTACHMENT; VIRUS CAPSID; VIRUS CARCINOGENESIS; VIRUS GENOME; VIRUS SURVIVAL; VIRUS TRANSMISSION;

HPV; HPV16; L2; MATURATION; PAPILLOMAVIRIDAE; VIRION;

AMINO ACID SEQUENCE; CAPSID PROTEINS; CONSERVED SEQUENCE; GENES, VIRAL; HEPARAN SULFATE PROTEOGLYCANS; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; PROTEIN FOLDING; PROTEIN INTERACTION MAPPING; VIRUS ASSEMBLY; VIRUS INTERNALIZATION;

HUMAN PAPILLOMAVIRUS; MIRIDAE; PAPILLOMAVIRIDAE;

EID: 84884356871     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.05.038     Document Type: Article

References (69)

1. Abban C.Y., Meneses P.I. Usage of heparan sulfate, integrins, and FAK in HPV16 infection. Virology 2010, 403:1-16.
2. Bachmann M.F., Rohrer U.H., Kundig T.M., Burki K., Hengartner H., Zinkernagel R.M. The influence of antigen organization on B cell responsiveness. Science 1993, 262:1448-1451.
3. Bergant M., Banks L. SNX17 facilitates infection with diverse papillomavirus types. J. Virol. 2013, 87:1270-1273.
4. Bergant Marusic M., Ozbun M.A., Campos S.K., Myers M.P., Banks L. Human papillomavirus L2 facilitates viral escape from late endosomes via sorting nexin 17. Traffic 2012, 13:455-467.
5. Bienkowska-Haba M., Patel H.D., Sapp M. Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS pathog. 2009, 5:e1000524.
6. Bienkowska-Haba M., Williams C., Kim S.M., Garcea R.L., Sapp M. Cyclophilins facilitate dissociation of the human papillomavirus type 16 capsid protein L1 from the L2/DNA complex following virus entry. J. Virol. 2012, 86:9875-9887.
7. Bird G., O'Donnell M., Moroianu J., Garcea R.L. Possible role for cellular karyopherins in regulating polyomavirus and papillomavirus capsid assembly. J. Virol. 2008, 82:9848-9857.
8. Buck C.B., Cheng N., Thompson C.D., Lowy D.R., Steven A.C., Schiller J.T., Trus B.L. Arrangement of L2 within the papillomavirus capsid. J. Virol. 2008, 82:5190-5197.
9. Buck C.B., Thompson C.D., Pang Y.Y., Lowy D.R., Schiller J.T. Maturation of papillomavirus capsids. J. Virol. 2005, 79:2839-2846.
10. Buck C.B., Trus B.L. The papillomavirus virion: a machine built to hide molecular Achilles' heels. Adv. Exp. Med. Biol. 2012, 726:403-422.
11. Caldwell E.E., Nadkarni V.D., Fromm J.R., Linhardt R.J., Weiler J.M. Importance of specific amino acids in protein binding sites for heparin and heparan sulfate. Int. J. Biochem. Cell Biol. 1996, 28:203-216.
12. Campos S.K., Chapman J.A., Deymier M.J., Bronnimann M.P., Ozbun M.A. Opposing effects of bacitracin on human papillomavirus type 16 infection: enhancement of binding and entry and inhibition of endosomal penetration. J. Virol. 2012, 86:4169-4181.
13. Carter J.J., Wipf G.C., Benki S.F., Christensen N.D., Galloway D.A. Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J. Virol. 2003, 77:11625-11632.
14. Chen X.S., Casini G., Harrison S.C., Garcea R.L. Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. J. Mol. Biol. 2001, 307:173-182.
15. Chen X.S., Garcea R.L., Goldberg I., Casini G., Harrison S.C. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol. Cell 2000, 5:557-567.
16. Chen X.S., Stehle T., Harrison S.C. Interaction of polyomavirus internal protein VP2 with the major capsid protein VP1 and implications for participation of VP2 in viral entry. EMBO J. 1998, 17:3233-3240.
17. Christensen N.D., Cladel N.M., Reed C.A., Budgeon L.R., Embers M.E., Skulsky D.M., McClements W.L., Ludmerer S.W., Jansen K.U. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 2001, 291:324-334.
18. Conway M.J., Alam S., Ryndock E.J., Cruz L., Christensen N.D., Roden R.B., Meyers C. Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J. Virol. 2009, 83:10515-10526.
19. Culp T.D., Spatz C.M., Reed C.A., Christensen N.D. Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology 2007, 361:435-446.
20. Dasgupta J., Bienkowska-Haba M., Ortega M.E., Patel H.D., Bodevin S., Spillmann D., Bishop B., Sapp M., Chen X.S. Structural basis of oligosaccharide receptor recognition by human papillomavirus. J. Biol. Chem. 2011, 286:2617-2624.
21. Day P.M., Baker C.C., Lowy D.R., Schiller J.T. Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc. Natl. Acad. Sci. USA 2004, 101:14252-14257.
22. Day P.M., Gambhira R., Roden R.B., Lowy D.R., Schiller J.T. Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J. Virol. 2008, 82:4638-4646.
23. Day P.M., Lowy D.R., Schiller J.T. Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 2003, 307:1-11.
24. Day P.M., Lowy D.R., Schiller J.T. Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids. J. Virol. 2008, 82:12565-12568.
25. Day P.M., Schiller J.T. The role of furin in papillomavirus infection. Future Microbiol. 2009, 4:1255-1262.
26. Day P.M., Thompson C.D., Buck C.B., Pang Y.Y., Lowy D.R., Schiller J.T. Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J. Virol. 2007, 81:8784-8792.
27. Day P.M., Thompson C.D., Schowalter R.M., Lowy D.R., Schiller J.T. Identification of a role for the trans-golgi network in human papillomavirus 16 pseudovirus Infection. J. Virol. 2013, 87:3862-3870.
28. Doorbar J. The papillomavirus life cycle. J. Clin. Virol. 2005, 32(1):S7-15.
29. Evander M., Frazer I.H., Payne E., Qi Y.M., Hengst K., McMillan N.A. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J. Virol. 1997, 71:2449-2456.
30. Florin L., Sapp M., Spoden G.A. Host-cell factors involved in papillomavirus entry. Med. Microbiol. Immunol. 2012, 201:437-448.
31. Giroglou T., Florin L., Schafer F., Streeck R.E., Sapp M. Human papillomavirus infection requires cell surface heparan sulfate. J. Virol. 2001, 75:1565-1570.
32. Huang H.S., Lambert P.F. Use of an in vivo animal model for assessing the role of integrin alpha(6)beta(4) and syndecan-1 in early steps in papillomavirus infection. Virology 2012, 433:395-400.
33. Ishii Y., Kondo K., Matsumoto T., Tanaka K., Shinkai-Ouchi F., Hagiwara K., Kanda T. Thiol-reactive reagents inhibits intracellular trafficking of human papillomavirus type 16 pseudovirions by binding to cysteine residues of major capsid protein L1. J. Virol. 2007, 4:110.
34. Johnson K.M., Kines R.C., Roberts J.N., Lowy D.R., Schiller J.T., Day P.M. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J. Virol. 2009, 83:2067-2074.
35. Joyce J.G., Tung J.S., Przysiecki C.T., Cook J.C., Lehman E.D., Sands J.A., Jansen K.U., Keller P.M. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J. Biol. Chem. 1999, 274:5810-5822.
36. Kämper N., Day P.M., Nowak T., Selinka H.C., Florin L., Bolscher J., Hilbig L., Schiller J.T., Sapp M. A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J. Virol. 2006, 80:759-768.
37. Kemp T.J., Safaeian M., Hildesheim A., Pan Y., Penrose K.J., Porras C., Schiller J.T., Lowy D.R., Herrero R., Pinto L.A. Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®). Vaccine 2012, 31:165-170.
38. Kines R.C., Thompson C.D., Lowy D.R., Schiller J.T., Day P.M. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc. Natl. Acad. Sci. USA 2009, 106:20458-20463.
39. Knappe M., Bodevin S., Selinka H.C., Spillmann D., Streeck R.E., Chen X.S., Lindahl U., Sapp M. Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate. J. Biol. Chem. 2007, 282:27913-27922.
40. Lowe J., Panda D., Rose S., Jensen T., Hughes W.A., Tso F.Y., Angeletti P.C. Evolutionary and structural analyses of alpha-papillomavirus capsid proteins yields novel insights into L2 structure and interaction with L1. J. Virol 2008, 5:150.
41. Merle E., Rose R.C., LeRoux L., Moroianu J. Nuclear import of HPV11 L1 capsid protein is mediated by karyopherin alpha2beta1 heterodimers. J. Cell Biochem. 1999, 74:628-637.
42. Modis Y., Trus B.L., Harrison S.C. Atomic model of the papillomavirus capsid. EMBO J. 2002, 21:4754-4762.
43. Nelson L.M., Rose R.C., LeRoux L., Lane C., Bruya K., Moroianu J. Nuclear import and DNA binding of human papillomavirus type 45 L1 capsid protein. J. Cell Biochem. 2000, 79:225-238.
44. Nelson L.M., Rose R.C., Moroianu J. Nuclear import strategies of high risk HPV16 L1 major capsid protein. J. Biol. Chem. 2002, 277:23958-23964.
45. Nelson L.M., Rose R.C., Moroianu J. The L1 major capsid protein of human papillomavirus type 11 interacts with Kap beta2 and Kap beta3 nuclear import receptors. Virology 2003, 306:162-169.
46. Orozco J.J., Carter J.J., Koutsky L.A., Galloway D.A. Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers. J. Virol. 2005, 79:9503-9514.
47. Patterson N.A., Smith J.L., Ozbun M.A. Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate. J. Virol. 2005, 79:6838-6847.
48. Puisieux A., Ji J., Ozturk M. Annexin II up-regulates cellular levels of p11 protein by a post-translational mechanisms. Biochem. J. 1996, 313(1):51-55.
49. Raff A.B., Woodham A.W., Raff L.M., Skeate J.G., Yan L., Da Silva D.M., Schelhaas M., Kast W.M. The evolving field of human papillomavirus receptor research: a review of binding and entry. J. Virol. 2013.
50. Richards R.M., Lowy D.R., Schiller J.T., Day P.M. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc. Natl. Acad. Sci. USA 2006, 103:1522-1527.
51. Roden R.B., Lowy D.R., Schiller J.T. Papillomavirus is resistant to desiccation. J. Infectious Diseases 1997, 176:1076-1079.
52. Ryding J., Dahlberg L., Wallen-Ohman M., Dillner J. Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. J. Gen. Virol. 2007, 88:792-802.
53. Schafer F., Florin L., Sapp M. DNA binding of L1 is required for human papillomavirus morphogenesis in vivo. Virology 2002, 295:172-181.
54. Scheffer K.D., Gawlitza A., Spoden G.A., Zhang X.A., Lambert C., Berditchevski F., Florin L. Tetraspanin CD151 mediates papillomavirus type 16 endocytosis. J. Virol. 2013, 87:3435-3446.
55. Schelhaas M., Malmstrom J., Pelkmans L., Haugstetter J., Ellgaard L., Grunewald K., Helenius A. Simian virus 40 depends on ER protein folding and quality control factors for entry into host cells. Cell 2007, 131:516-529.
56. Schelhaas M., Shah B., Holzer M., Blattmann P., Kuhling L., Day P.M., Schiller J.T., Helenius A. Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLoS pathog. 2012, 8:e1002657.
57. Schiller J.T., Lowy D.R. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat. Rev. Microbiol. 2012, 10:681-692.
58. Selinka H.C., Florin L., Patel H.D., Freitag K., Schmidtke M., Makarov V.A., Sapp M. Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J. Virol. 2007, 81:10970-10980.
59. Shafti-Keramat S., Handisurya A., Kriehuber E., Meneguzzi G., Slupetzky K., Kirnbauer R. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J. Virol. 2003, 77:13125-13135.
60. Spoden G., Freitag K., Husmann M., Boller K., Sapp M., Lambert C., Florin L. Clathrin- and caveolin-independent entry of human papillomavirus type 16-involvement of tetraspanin-enriched microdomains (TEMs). PloS one 2008, 3:e3313.
61. Stehle T., Gamblin S.J., Yan Y., Harrison S.C. The structure of simian virus 40 refined at 3.1Å resolution. Structure 1996, 4:165-182.
62. Surviladze Z., Dziduszko A., Ozbun M.A. Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS pathog. 2012, 8:e1002519.
63. Surviladze Z., Sterk R.T., DeHaro S.A., Ozbun M.A. Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy. J. Virol. 2013, 87:2508-2517.
64. von Bubnoff A. Taking the gritty approach. IAVI Rep. 2012, 16:4-9.
65. Wang X., Meyers C., Wang H.K., Chow L.T., Zheng Z.M. Construction of a full transcription map of human papillomavirus type 18 during productive viral infection. J. Virol. 2011, 85:8080-8092.
66. Wang Z., Christensen N., Schiller J.T., Dillner J. A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J. Gen. Virol. 1997, 78(9):2209-2215.
67. Wolf M., Garcea R.L., Grigorieff N., Harrison S.C. Subunit interactions in bovine papillomavirus. Proc. Natl. Acad. Sci. USA 2010.
68. Woodham A.W., Da Silva D.M., Skeate J.G., Raff A.B., Ambroso M.R., Brand H.E., Isas J.M., Langen R., Kast W.M. The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PloS one 2012, 7:e43519.
69. Zhou J., Doorbar J., Sun X.Y., Crawford L.V., McLean C.S., Frazer I.H. Identification of the nuclear localization signal of human papillomavirus type 16 L1 protein. Virology 1991, 185:625-632.